NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of purchasers of investors that purchased or otherwise acquired Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART) common stock between March 11, 2019 and May 22, 2023, inclusive (the “Class Period”). Click Here to Join Investigation.
If you acquired Integra common stock during the Class Period and would like to discuss this case, please click here. You may also contact us by emailing pmayer@kaplanfox.com or calling (646) 315-9003.
If you are a member of the proposed Class, you may move the court no later than November 13, 2023 to serve as a lead plaintiff for the purported class. If you have losses, we encourage you to contact us to learn more about the lead plaintiff process.
On May 23, 2023, Integra disclosed in a filing with the U.S. Securities and Exchange Commission that the Company, "after consultation with the U.S. Food and Drug Administration (the ‘FDA'), initiated a voluntary global recall of all products manufactured in its Boston, Massachusetts facility (the ‘Boston facility’) distributed between March 1, 2018 and May 22, 2023[.]" Integra stated that it "identified through an internal investigation process in its Boston facility deviations with endotoxin testing that may have resulted in the release of products with higher levels of endotoxins than permitted by the product specifications[,]" and that it "decided to initiate the voluntary recall and extend the temporary halt of manufacturing at its Boston facility to implement additional detection and quality controls." According to the complaint, The recall included Integra's SurgiMend®, PriMatrix®, Revize™ and TissueMend™ products, in which higher levels of endotoxins could have increased the risk of post-operative fever and other complications for the patients who received these medical implants.
Following this news, the price of Integra stock price fell $10.24 per share, or 20.19%, to close at $40.48 per share on May 23, 2023.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in complex litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this Notice, your rights, or your interests, please contact:
Pamela Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
E-mail: pmayer@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax: (415) 772-4707
E-mail: lking@kaplanfox.com
